Press Release Details

Colfax Reports First Quarter Results

May 8, 2009

RICHMOND, Va., May 8, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Colfax Corporation (NYSE: CFX), a global leader in engineered fluid handling products and systems, today announced financial results for the first quarter ended April 3, 2009. On a year-over-year basis, highlights for the quarter include:

First quarter of 2009 (all comparisons versus the first quarter of 2008)

    --  Net income of $6.9 million (16 cents per share - basic and diluted);
        Adjusted net income (as defined below) of $10.4 million (24 cents per
        share), an increase of 2.1% including negative currency effects of 5
        cents per share
    --  Net sales of $136.3 million, an increase of 4.3%; Organic sales growth
        (as defined below) of 17.9%
    --  Operating income of $11.8 million; Adjusted operating income (as defined
        below) of $17.1 million, a decrease of 6.6% including negative currency
        effects of $3.4 million
    --  EBITDA (as defined below) of $15.2 million; Adjusted EBITDA (as defined
        below) of $20.5 million, a decrease of 7.0% including negative currency
        effects of $3.7 million
    --  First quarter orders of $120.8 million, a decrease of 33.0%; Organic
        order decline (as defined below) of 25.5%

    --  Backlog of $305.6 million at period end

Adjusted net income, adjusted net income per share, adjusted operating income, EBITDA, adjusted EBITDA, organic sales growth and organic order growth are not financial measures calculated in accordance with generally accepted accounting principles in the U.S. ("GAAP"). See below for a description of the measures' usefulness and a reconciliation of these measures to their most directly comparable GAAP financial measures.

"We had a solid first quarter thanks to our sizable backlog entering 2009," said John Young, president and CEO of Colfax Corporation. "Organic sales were up 18% driven by particularly strong growth in the commercial marine, oil and gas, power generation and global navy end markets. However, global economic conditions continued to deteriorate in the quarter as reflected in our organic orders which declined 25%. We've initiated several cost reduction measures across the company in response to the decline in demand. We believe economic conditions could remain difficult for the balance of the year and now expect organic sales for the year to be down between 2% and 4%. We expect adjusted earnings per share of $1.00 to $1.07 for 2009 which includes about 7 cents of negative currency impact compared to our prior guidance of $1.10 to $1.17."

He added, "We will remain agile and will continue to make adjustments to our businesses as conditions warrant. Our strong financial position provides flexibility and allows us to pursue acquisitions while also funding our breakthrough growth initiatives. Despite current economic conditions, we'll continue to deliver unsurpassed value to our customers and execute on our long term strategies to drive profitable sales growth."

Non-GAAP Financial Measures

Colfax has provided in this press release financial information that has not been prepared in accordance with GAAP. These non-GAAP financial measures are adjusted net income, adjusted net income per share, adjusted operating income, EBITDA, adjusted EBITDA, organic sales growth and organic order growth. Adjusted net income, adjusted net income per share, adjusted operating income and adjusted EBITDA exclude asbestos liability and defense cost (income) and asbestos coverage litigation expense, certain legacy legal charges, certain due diligence costs, certain severance and asset impairment charges as well as one time initial public offering-related costs to the extent they impact the periods presented. Adjusted net income also reflects interest expense as if the initial public offering (IPO) had occurred at the beginning of 2007 and presents income taxes at an effective tax rate of 32% in 2009 and 34% in 2008. Adjusted net income per share in 2008 assumes the 44,006,026 shares outstanding at the closing of the IPO to be outstanding since January 1, 2007. Organic sales growth and organic order growth (decline) exclude the impact of foreign exchange rate fluctuations. These non-GAAP financial measures assist Colfax in comparing its operating performance on a consistent basis because, among other things, they remove the impact of changes in our capital structure and asset base, non-recurring items such as IPO-related costs, legacy asbestos issues (except in the case of EBITDA) and items outside the control of its operating management team.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of non-GAAP financial measures presented above to GAAP results has been provided in the financial tables included in this press release.

Conference Call and Webcast

Colfax will host a conference call to provide details about its results and business strategy on Friday, May 8 at 8:00 a.m. EDT. The call will be open to the public through 719-325-4794 or 877-857-6176 and webcast via Colfax's website at http://www.colfaxcorp.com under the "Investor Relations" section. Access to a supplemental slide presentation can also be found at the Colfax website under the same heading. Both the audio of this call and the slide presentation will be archived on the website later today and will be available until the next quarterly call.

About Colfax Corporation

Colfax Corporation is a global leader in critical fluid-handling solutions, including the manufacture of positive displacement industrial pumps and valves used in global oil & gas, power generation, marine, naval and a variety of other industrial applications. Key product brands include Allweiler, Fairmount Automation, Houttuin, Imo, LSC, Portland Valve, Tushaco, Warren and Zenith. Colfax is traded on the NYSE under the ticker "CFX." Additional information about Colfax's products, businesses and practices is available at www.colfaxcorp.com

Cautionary Note Concerning Forward Looking Statements

This press release contains forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Colfax's plans, objectives, expectations and intentions and other statements that are not historical or current facts. Forward-looking statements are based on Colfax's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Colfax's results to differ materially from current expectations include, but are not limited to factors detailed in Colfax's reports filed with the U.S. Securities and Exchange Commission as well as its Annual Report on Form 10-K under the caption "Risk Factors". In addition, these statements are based on a number of assumptions that are subject to change. This press release speaks only as of this date. Colfax disclaims any duty to update the information herein.


                             Colfax Corporation
               Condensed Consolidated Statements of Operations
                 Dollars in thousands, except per share data
                                (unaudited)

                                                          Three Months Ended
                                                          ------------------
                                                  April 3, 2009 March 28, 2008
                                                  ------------- --------------

    Net sales                                          $136,323       $130,651
    Cost of sales                                        88,308         82,473
                                                         ------         ------
    Gross profit                                         48,015         48,178
    Selling, general and administrative expenses         30,187         28,507
    Research and development expenses                     1,407          1,381
    Asbestos liability and defense costs                  1,645            278
    Asbestos coverage litigation expenses                 2,966          3,139
                                                          -----          -----

    Operating income                                     11,810         14,873
    Interest expense                                      1,846          4,497
                                                          -----          -----

    Income before income taxes                            9,964         10,376
    Provision for income taxes                            3,103          3,578
                                                          -----          -----

    Net income                                           $6,861         $6,798
                                                         ======         ======

    Net income per share-basic and diluted                $0.16          $0.31
                                                          =====          =====



                            Colfax Corporation
           Reconciliation of GAAP to non-GAAP Financial Measures
                Dollars in thousands, except per share data
                                (unaudited)

                                              Three Months Ended
                                              ------------------
                                        April 3, 2009  March 28, 2008
                                        -------------  --------------

    EBITDA
    Net income                                 $6,861          $6,798

    Interest expense                            1,846           4,497
    Provision for income taxes                  3,103           3,578
    Depreciation and amortization               3,373           3,695
                                                -----           -----

    EBITDA                                    $15,183         $18,568
                                              =======         =======
    EBITDA margin                                11.1%           14.2%

    Adjusted EBITDA
    Net income                                 $6,861          $6,798

    Interest expense                            1,846           4,497
    Provision for income taxes                  3,103           3,578
    Depreciation and amortization               3,373           3,695
    Severance and asset impairment costs          661               -
    Asbestos liability and defense costs        1,645             278
    Asbestos coverage litigation expense        2,966           3,139
                                                -----           -----

    Adjusted EBITDA                           $20,455         $21,985
                                              =======         =======
    Adjusted EBITDA margin                       15.0%           16.8%

    Adjusted Net Income and Adjusted
     Earnings per Share
    Net income                                 $6,861          $6,798

    Severance and asset impairment costs          661               -
    Asbestos liability and defense costs        1,645             278
    Asbestos coverage litigation expense        2,966           3,139
    Interest adjustment to effect IPO at
     beginning of period                            -           1,577
    Tax adjustment to effective rate of 32%
     and 34%, respectively                     (1,773)         (1,648)
                                               ------          ------

    Adjusted net income                       $10,360         $10,144
                                              =======         =======
    Adjusted net income margin                    7.6%            7.8%

    Weighted average shares outstanding
     - diluted                             43,312,306               -
    Shares outstanding at closing of IPO            -      44,006,026
    Adjusted net income per share               $0.24           $0.23
                                                =====           =====

    Net income per share-basic and diluted
     in accordance with GAAP                    $0.16           $0.31
                                                =====           =====

    Adjusted Operating Income
    Operating income                          $11,810         $14,873

    Severance and asset impairment costs          661               -
    Asbestos liability and defense costs        1,645             278
    Asbestos coverage litigation expense        2,966           3,139
                                                -----           -----

    Adjusted operating income                 $17,082         $18,290
                                              =======         =======
    Adjusted operating income margin             12.5%           14.0%



                                 Colfax Corporation
                              Sales and Orders Growth
                                Dollars in millions
                                    (unaudited)


                                     Sales          Orders      Backlog at
                                    -------        --------       Period
                                   $      %        $      %         End
                                   --------        --------     ----------
    Three Months Ended
     March 28, 2008             $130.7          $180.3         $353.6

    Components of Growth:
    Existing Businesses           23.4   17.9%   (45.9) (25.5%)  (9.8)  (2.8%)
    Foreign Currency
     Translation                 (17.8) (13.6%)  (13.6)  (7.5%) (38.2) (10.8%)
                                 -----           -----          -----
              Total Growth         5.6    4.3%   (59.5) (33.0%) (48.0) (13.6%)
                                ------          ------          ------
    Three Months Ended
     April 3, 2009              $136.3          $120.8         $305.6
                                ======          ======         ======



                              Colfax Corporation
            Reconciliation of Projected 2009 Net Income Per Share to
                          Adjusted Net Income Per Share
                              Amounts in Dollars
                                 (unaudited)


                                                        EPS Range
                                                        ---------

    Projected net income per share - fully diluted     $0.69 $0.76

    Severance and asset impairment costs *              0.01  0.01
    Asbestos coverage litigation                        0.19  0.19
    Asbestos liability and defense costs                0.11  0.11
                                                        ----  ----

    Projected adjusted net income per share - fully
     diluted                                           $1.00 $1.07
                                                       ===== =====


      * Actual costs for first quarter 2009

SOURCE Colfax Corporation

http://www.colfaxcorp.com

Copyright (C) 2009 PR Newswire. All rights reserved